Business
Amneal is a diversified global biopharmaceutical company that develops, manufactures, markets, and distributes essential medicines across Affordable Medicines, Specialty, and AvKARE.
Amneal revenue rose 8.0% to $3.0B, net income turned positive at $72.1M, and free cash flow rose 11.0%.
The read at a glance✓ Audited against SEC data
- Business mix — Generics, specialty drugs, and AvKARENote
- Revenue — Revenue rose 8.0% to $3.0BOK
- Profitability — Net income turned positiveOK
- Cash — Free cash flow rose 11.0%OK
- Balance sheet — Debt rose 7.8%; equity stayed negativeWatch
- Insiders — 0 buys / 13 sellsWatch
- Accounting — Altman-Z distress; EQ safeWatch
Where the revenue comes from
Fiscal 2025, as Amneal Pharmaceuticals, Inc. reports it. History and quarterly detail are in the app.
- Affordable Medicines$1.7B
- AvKARE$744.7M
- Specialty$528.5M
Latest filings
- 8-K · Company announcement2026-08-10
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-08-03
- 8-K · Company announcement2026-07-31
- 8-K · Company announcement2026-07-30
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Amneal Pharmaceuticals, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.